Opus Genetics Inc(IRD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:40 PM ET (Korea 10/31 07:40)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.38 | Insider Own | 18.89% | Shs Outstand | 82.7M | Perf Week | 5.76% |
| Market Cap | 0.31B | Forward P/E | - | EPS next Y | 31.68% | Insider Trans | -13.13% | Shs Float | 67.5M | Perf Month | -18.63% |
| Enterprise Value | 0.25B | PEG | - | EPS next Q | -0.15 | Inst Own | 67.48% | Short Float | 19.77% | Perf Quarter | 0.82% |
| Income | -0.11B | P/S | 30.97 | EPS this Y | -28.82% | Inst Trans | 18.52% | Short Ratio | 5.36 | Perf Half Y | -28.6% |
| Sales | 0.01B | P/B | - | EPS next 5Y | 33.47% | ROA | -163.5% | Short Interest | 13.34M | Perf YTD | 82.59% |
| Book/sh | -0.16 | P/C | 3.44 | EPS past 3/5Y | - 31.49% | ROE | -4796.52% | 52W High | -48.09% ($7.07) | Perf Year | 86.29% |
| Cash/sh | 1.07 | P/FCF | - | Sales past 3/5Y | -29.11% - | ROIC | -463.48% | 52W Low | 115.88% ($1.70) | Perf 3Y | 30.6% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 24.84% | Gross Margin | 99.46% | Volatility(W/M) | 7.7% 7.84% | Perf 5Y | -6.85% |
| Dividend TTM | - | EV/Sales | 25.63 | Sales Y/Y TTM | -36.09% | Oper. Margin | -513.47% | ATR (14) | 0.33 | Perf 10Y | -95.45% |
| Dividend Ex-Date | - | Quick Ratio | 12.19 | EPS Q/Q | -18.7% | Profit Margin | -1091.82% | RSI (14) | 39.68 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.19 | Sales Q/Q | -73.8% | SMA20 | -8.44% ($4.01) | Beta | 0.77 | Target Price | $13.47 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -17.89% ($4.47) | Rel Volume | 0.41 | Prev Close | $3.65 |
| Employees | 28 | LT Debt/Eq | - | EPS/Sales Surpr. | 10.66% -71.27% | SMA200 | -12.26% ($4.18) | Avg Volume(3M) | 2.49M | Price | $3.67 |
| IPO | 2004/11/30 | Option/Short | Yes/Yes | Trades | 4620 | Volume | 1,020,056 | Change | 0.55% |
🧬 This is a US biotech company developing gene therapies for ophthalmology indications, including inherited retinal diseases (IRD). The company is advancing clinical-stage therapeutic candidates that target the genetic defects responsible for retinal degeneration, and maintains a pipeline aimed at addressing unmet medical needs in the rare eye disease space.
Over the past 1 year, roughly in the middle
48% below its 1-year high.
Traded less than usual. That is 41% of its average volume.
IRD has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -28.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,097. Peers typically go for $1,268. Compared with its own 1-year average, it is 45% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -6.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 67.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #263 of 597 in the industry
Based on market cap of $305M.
PRLD#261 Prelude Therapeutics Inc $310M PER - 
AGEN#262 Agenus Inc $309M PER 2.6 IRD#263 Opus Genetics Inc $305M PER - 
BNTC#264 Benitec Biopharma Inc $305M PER - 
SABS#265 SAB Biotherapeutics Inc $305M PER - 
FAQ
What kind of company is IRD?
IRD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IRD?
The market cap of IRD is approximately $305M, ranking 3,620 within its sector.
What is the 52-week high and low for IRD?
IRD has recorded a 52-week high of $7.07 and a low of $1.70.
